Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 18:13:1186198.
doi: 10.3389/fonc.2023.1186198. eCollection 2023.

The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to 2022

Zhengyu Yu  1 , Li Xie  2 , Jing Zhang  2 , Hua Lin  2 , Ting Niu  1
Affiliations

The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to 2022

Zhengyu Yu et al. Front Oncol. .

Abstract

Background: The topic of minimal residual disease (MRD) has emerged as a crucial subject matter in the domain of oncology in recent years. The detection and monitoring of MRD have become essential for the diagnosis, treatment, and prognosis of various types of malignancy.

Aims: The purpose of this study is to explore the research trends, hotspots, and frontiers of MRD in the last two decades through bibliometric analysis.

Methods: We employed Web of Science databases to carry out a bibliometric visualization analysis of research on 8,913 academic papers about MRD research from 2002 to 2022. VOSviewer, CiteSpace, RStudio, and a bibliometric online analysis platform were mainly used to conduct co-occurrence analysis and cooperative relationship analysis of countries/regions, institutions, journals, and authors in the literature. Furthermore, co-occurrence, co-citation, and burst analyses of keyword and reference were also conducted to generate relevant knowledge maps.

Results: In the past 20 years, the number of MRD research papers has presented an overall rising trend, going through three stages: a plateau, development, and an explosion. The output of articles in the United States was notably superior and plays a dominant role in this field, and the Netherlands had the highest average citation per article. The most productive and influential institution was the University of Texas MD Anderson Cancer Center. Blood published the most papers and was the most cited journal. A collection of leading academics has come to the fore in the research field, the most prolific of which is Kantarjian HM. It was found that the application of MRD in "acute myeloid leukemia", "acute lymphoblastic leukemia", "multiple myeloma", as well as the detection technology of MRD, are the research hotspots and frontiers in this domain. Furthermore, we analyzed the co-citation network of references and found that the top 10 co-cited references were all associated with MRD in hematological malignancies.

Conclusion: This bibliometric visualization analysis conducted a thorough exploration into the research hotspots and trends in MRD from 2002 to 2022. Our findings can aid researchers in recognizing possible collaborations, guiding future research directions, and fostering the growth of MRD detection and monitoring technologies.

Keywords: CiteSpace; VOSviewer; bibliometrics; hematological malignancies; minimal residual disease (MRD).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of publications on minimal residual disease (MRD) from 2002 to 2022.
Figure 2
Figure 2
(A) The geographical distribution map based on the total publications of major countries/regions. (B) The changing trends in the number of publications in the top 10 countries/regions from 2002 to 2022. (C) The SCP and MCP in the top 10 corresponding author’s country/region. (D) Collaboration network between countries/regions related to MRD.
Figure 3
Figure 3
(A) The world distribution map of the top 10 institutions in the field of MRD. (B) The top ten institutions in the MRD field and their respective output performance. (C) The knowledge map of the institutions’ cooperation network related to MRD.
Figure 4
Figure 4
(A) Map of the distribution of core journals in the MRD field. (B) Core journals in the MRD field and their respective output performance and influence. (C) The dynamics of annual cumulative publications for core journals in the MRD field. (D) The heatmap of the annual publication dynamics of core journals in the MRD field. (Each box represents the yearly count of papers released by the journal, with greater brightness indicating a larger number of papers released).
Figure 5
Figure 5
(A) The co-occurrence visualization map of co-cited journals. (B) The dual-map overlay of journals related to MRD research.
Figure 6
Figure 6
(A) The knowledge map of keyword co-occurrence network in the MRD research field. (The labels indicate high betweenness centrality keywords). (B) The knowledge map of keyword clustering network in the MRD research field. (C) The keyword cloud.
Figure 7
Figure 7
The top 24 keywords with the strongest citation bursts from 2002 to 2022.
Figure 8
Figure 8
(A) The knowledge map of high frequency co-cited references network related to MRD. (B) The knowledge map of high betweenness centrality co-cited references network related to MRD.
Figure 9
Figure 9
The top 22 references with the strongest citation bursts from 2002 to 2022.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kreidieh F, Abou Dalle I, Moukalled N, El-Cheikh J, Brissot E, Mohty M, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol (2022) 116(3):330–40. doi: 10.1007/s12185-022-03416-7 - DOI - PubMed
    1. Koschade SE, Stratmann JA, Finkelmeier F, Wagner S, Chromik J, Steffen B, et al. Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations. Ann Hematol (2022) 101(8):1703–10. doi: 10.1007/s00277-022-04862-3 - DOI - PMC - PubMed
    1. Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov (2022) 3(1):66–81. doi: 10.1158/2643-3230.BCD-21-0095 - DOI - PMC - PubMed
    1. Prindull G. Minimal residual neoplastic disease–concept, pathogenesis, and supplementary therapeutic possibilities. Cancer Treat Rev (1986) 13(3):177–94. doi: 10.1016/0305-7372(86)90004-6 - DOI - PubMed
    1. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol (2015) 16(4):465–74. doi: 10.1016/S1470-2045(15)70082-3 - DOI - PMC - PubMed